RT Journal Article
SR Electronic
T1 Controlling the pandemic during the SARS-CoV-2 vaccination rollout: a modeling study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.03.24.21254188
DO 10.1101/2021.03.24.21254188
A1 Viana, João
A1 van Dorp, Christiaan H.
A1 Nunes, Ana
A1 Gomes, Manuel C.
A1 van Boven, Michiel
A1 Kretzschmar, Mirjam E.
A1 Veldhoen, Marc
A1 Rozhnova, Ganna
YR 2021
UL http://medrxiv.org/content/early/2021/04/04/2021.03.24.21254188.abstract
AB There is a consensus that mass vaccination against SARS-CoV-2 will ultimately end the COVID-19 pandemic. However, it is not clear when and which control measures can be relaxed during the rollout of vaccination programmes. We investigate relaxation scenarios using an age-structured transmission model that has been fitted to age-specific seroprevalence data, hospital admissions, and projected vaccination coverage for Portugal. Our analyses suggest that the pressing need to restart socioeconomic activities could lead to new pandemic waves, and that substantial control efforts prove necessary throughout 2021. Using knowledge on control measures introduced in 2020, we anticipate that relaxing measures completely or to the extent as in autumn 2020 could launch a wave starting in April 2021. Additional waves could be prevented altogether if measures are relaxed as in summer 2020 or in a step-wise manner throughout 2021. We discuss at which point control of COVID-19 would be achieved for each scenario.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNot applicableFunding StatementG.R., J.V., A.N., M.C.G. were supported by FCT project reference 131\textunderscore596787873, awarded to G.R. M.V. was supported by the European Union H2020 ERA project (No 667824 - EXCELLtoINNOV).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Not applicableAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data used in this study are publicly available at https://github.com/lynxgav/COVID19-vaccination. https://github.com/lynxgav/COVID19-vaccination